These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Introduction: missing the target with lipid-lowering therapy. Hunninghake DB; McKenney JM Am J Manag Care; 2000 Nov; 6(19 Suppl):S992-6. PubMed ID: 11187370 [No Abstract] [Full Text] [Related]
43. Management of hypercholesterolaemia in the patient with diabetes. Packard C; Olsson AG Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606 [TBL] [Abstract][Full Text] [Related]
44. Hypercholesterolemia in children. Kavey RE Am Fam Physician; 2000 Feb; 61(3):633-4, 636. PubMed ID: 10695576 [No Abstract] [Full Text] [Related]
46. Reducing heart disease: an international health priority. A growing body of evidence highlights the central role of lipids. Minerva Cardioangiol; 1995 Apr; 43(4):XI-XII. PubMed ID: 7644083 [No Abstract] [Full Text] [Related]
48. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465 [TBL] [Abstract][Full Text] [Related]
49. Genetics and molecular biology: rationale for targeting high-density lipoprotein cholesterol for therapeutic intervention. Mukherjee S Curr Opin Lipidol; 2006 Oct; 17(5):602-5. PubMed ID: 16960508 [No Abstract] [Full Text] [Related]
50. Cholesterol. Interpreting the new guidelines. Becker DM; LaRosa JH; Watson JE Am J Nurs; 1989 Dec; 89(12):1621-4. PubMed ID: 2589418 [No Abstract] [Full Text] [Related]
51. HDL testing should be routine part of assessments of coronary heart disease risk, says consensus panel. Clin Pharm; 1992 May; 11(5):378, 381. PubMed ID: 1582128 [No Abstract] [Full Text] [Related]
52. [Risk patients are often insufficiently treated. LDL cholesterol to be held down even more vigorously]. MMW Fortschr Med; 2004 Oct; 146(44):56-7. PubMed ID: 15566253 [No Abstract] [Full Text] [Related]
53. Adult treatment panel III and the management of dyslipidemia risk factors. Stein EA Postgrad Med; 2002 Oct; 112(4 Suppl):12-7. PubMed ID: 19667595 [TBL] [Abstract][Full Text] [Related]
54. The economics of lipid management. Mullins CD Manag Care; 2001 Nov; 10(11 Suppl):17-8; discussion 19-24. PubMed ID: 11761626 [No Abstract] [Full Text] [Related]
57. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Geiss HC; Otto C; Parhofer KG Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435 [TBL] [Abstract][Full Text] [Related]
58. [Hyperlipidemia: decreasing lipid values and effects of statins]. Mathes P Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762 [No Abstract] [Full Text] [Related]
59. New cholesterol guidelines emphasize risk assessment. Grundy SM Am J Manag Care; 2002 Jan; Suppl():1, 3. PubMed ID: 11833450 [No Abstract] [Full Text] [Related]
60. Coping with cholesterol. The waxy buildup in our blood vessels is a leading cause of fatal heart disease. Do dietary supplements add anything to the arsenal against it? Kalb C Newsweek; 2000 Jun; 135(25):73, 75. PubMed ID: 10977154 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]